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Purpose	Access site complications following peripheral vascular intervention (PVI) are associated with prolonged
hospitalization and increased mortality. Prediction of access site complication risk may optimize PVI
care; however, there is no tool designed for this. We aimed to create a clinical scoring tool to stratify
patients according to their risk of developing access site complications after PVI.
Methods	
The Society for Vascular Surgery’s Vascular Quality Initiative database yielded 27,997 patients who had
undergone PVI at 131 North American centers. Clinically and statistically significant preprocedural risk
factors associated with in-hospital, post-PVI access site complications were included in a multivariate
logistic regression model, with access site complications as the outcome variable. A predictive model
was developed with a random sample of 19,683 (70%) PVI procedures and validated in 8,314 (30%).
Results		Access site complications occurred in 939 (3.4%) patients. The risk tool predictors are female gender,
age > 70 years, white race, bedridden ambulatory status, insulin-treated diabetes mellitus, prior minor
amputation, procedural indication of claudication, and nonfemoral arterial access site (model c-statistic =
0.638). Of these predictors, insulin-treated diabetes mellitus and prior minor amputation were protective
of access site complications. The discriminatory power of the risk model was confirmed by the validation
dataset (c-statistic = 0.6139). Higher risk scores correlated with increased frequency of access site
complications: 1.9% for low risk, 3.4% for moderate risk and 5.1% for high risk.
Conclusions	
The proposed clinical risk score based on eight preprocedural characteristics is a tool to stratify patients
at risk for post-PVI access site complications. The risk score may assist physicians in identifying
patients at risk for access site complications and selection of patients who may benefit from bleeding
avoidance strategies. (J Patient-Centered Res Rev. 2016;3:20-29.)
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Puncture site hematomas associated with and without
pseudoaneurysm are the most common complication
in patients undergoing peripheral vascular intervention
(PVI) and result in increased length of hospitalization,
discharge to nursing home and rehabilitation, and inhospital and long-term mortality.1-5 Many models have
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been developed to calculate patient risk for bleeding
complications after percutaneous coronary intervention
(PCI) to assist clinicians in using bleeding avoidance
strategies in patients at higher risk.6-11 Although
patients with coronary disease undergoing PCI have
similar comorbidities as patients with PCI undergoing
PVI, prior studies have shown that risk factors for PVI
access site complications (ASC) differ from those for
patients undergoing PCI.12 Presently, no preprocedural
tool exists to assess patients for risk of post-PVI ASC.
Using data from the Society for Vascular Surgery
Original Research

Patient Safety Organization’s Vascular Quality
Initiative (VQI), we identified clinical risk factors for
post-PVI ASC and developed and validated a clinical
tool to predict patient risk.

METHODS

Study Population
This study retrospectively analyzed data for 36,529 PVI
procedures performed from August 2007 to January 2014
in 131 American and Canadian centers participating in
the VQI. A description of the VQI has been previously
published.13 Immediate and in-hospital events were
collected by personnel or providers involved in each
patient’s care at each center participating in the VQI, or
via retrospective chart review by designated data entry
personnel. ASCs were site-determined by examination
of the medical record, and validation occurred when
fields were filled with data outside preset parameters and
by comparison with billing information. De-identified
data were analyzed and individual patient consent was
not obtained. Aurora Health Care’s Institutional Review
Board prospectively approved the study.
Definitions
ASC was defined as the presence of a hematoma at the
procedural puncture site associated with or without
pseudoaneurysm prior to discharge and classified as
requiring no intervention or requiring blood transfusion,
thrombin injection or operation. Diabetic patients were
analyzed by their treatment regimen: no insulin (i.e.
diet and lifestyle modification and oral hypoglycemic
medications) or on insulin. Procedural urgency was
considered emergent if the patient was treated within
hours of presentation, urgent if treatment was expected
in the same hospital stay, or elective if it was scheduled
on an outpatient basis. Indications consisted of
claudication, rest pain, tissue loss or acute ischemia.
Statistical Methods
All categorical variables were described as frequencies
and percentages and compared using chi-square tests.
Continuous variables were described as mean, range
and standard deviation and were compared using
t-test. Only one procedure was randomly included for
patients with multiple PVIs, and patients who died or
transferred to another hospital were excluded as they
represent a censured population (Figure 1). Missing
data across all the covariates was 5.6% overall, and
patients with missing data related to age, gender, race,
Original Research

smoking history, body mass index, ambulatory status,
diabetes, dialysis dependence, procedural indication
and urgency, arterial access site, ASC, prior aneurysm
repair, prior amputation or prior PVI were excluded. A
random sample comprising 70% (n=19,683) of patients
was used as derivation data to develop the predictive
model, and the remaining 30% (n=8,314) of the study
group was used to validate the model.
VQI Registry: August 2007 to January 2014
36,529 PVI at >130 centers
Exclusions
>1 procedure on individual patient (7,047)
Missing ASC data (301)
Died/transferred ≤24 hours after procedure (52)
Age <40 years (27)
Missing ≥1 data element (1,085)
Study population
27,997

Derivation cohort (70%)
19,683 procedures

Validation cohort (30%)
8,314 procedures

Figure 1. Population flow diagram displaying which

patients were included and excluded from the study.
ASC, access site complication; PVI, peripheral vascular
intervention; VQI, Vascular Quality Initiative.

Based on prior association to ASC and clinical relevance,
preprocedural characteristics were selected for initial
analysis (Table 1). Continuous variables were plotted
against rates for ASC to create dichotomous cut-off
points at which relationships became flat or nonlinear.
Thirteen characteristics were then entered in the initial
multivariate logistic regression model with post-PVI
ASC as the binary outcome variable. C-statistics
and the Hosmer-Lemeshow test were used to test the
goodness-of-fit for the model. Backward selection was
then used with a criterion of keeping P<0.05, which
resulted in the removal of five variables: body mass
index, dialysis dependence, smoking history, prior PVI
and prior aneurysm repair. This model was applied
to the remaining 30% of patients, and c-statistics and
Brier score were used to validate the model. The ASC
risk score was derived from this model by converting β
coefficients into integers and adding these eight integers
for each individual patient to determine their ASC risk.
From observation of the ASC risk distribution in the
www.aurora.org/jpcrr
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derivation cohort (n=19,683), three risk categories ––
low, medium and high –– were subjectively defined.
Given the importance of diabetes in the pathogenesis of
PVI and the potential for confounding that treatment of
diabetes and its complications may present, it was decided
a priori to apply propensity score matching to assess ASC
risk compared to nondiabetics. Demographic, clinical
and procedural variables were included in a logistic
regression model to predict a patient being diabetic

versus nondiabetic conditioned on the covariates found
in Table 2. We performed a 1:1 match on the logit of the
propensity score to four digits (0.0001) of the probability
of being diabetic. Conditional logistic regression was
used to produce odds ratios (OR) and 95% confidence
intervals (CI). Using the same method, a separate
analysis compared diabetics treated with insulin versus
nondiabetics and diabetics not taking insulin.
To study the relationship of antithrombotic agents and
closure devices by preprocedural risk, an unmatched
subpopulation analysis was achieved by applying

Table 1. Variables considered in modeling process
Demographics
Age (years)*
Gender
Race
Hispanic/Latino ethnicity
Body mass index*
Social history
Living status (home or other)
Preoperative ambulatory status
Smoking
Home medications
Aspirin
P2Y12 antagonist
Chronic anticoagulant
Medical history
Congestive heart failure
Chronic obstructive pulmonary disease
Hypertension
Diabetes
Dialysis
Coronary artery disease
American Society of Anesthesiologists physical status class
Laboratory results
Creatinine clearance* (Cockcroft-Gault formula)
Hemoglobin*
Surgical/Interventional history
Coronary artery bypass
Percutaneous coronary intervention
Lower extremity bypass
Carotid endarterectomy
Lower extremity aneurism repair
Carotid endarterectomy
Lower extremity aneurism repair
Peripheral vascular intervention
Major lower extremity amputation
Minor lower extremity amputation
Periprocedural
Indication
Urgency
Arterial access site (femoral or nonfemoral)
*Analyzed as a continuous and categorical variable.
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Table 2. Variables matched in the insulin-treated
diabetes propensity analysis
Demographics
Age (years)*
Gender
Race
Hispanic/Latino ethnicity
Body mass index*
Social history
Preoperative ambulatory status
Home medications
Aspirin
P2Y12 antagonist
Chronic anticoagulant
Medical history
Anemia
Congestive heart failure
Hypertension
Laboratory results
Creatinine clearance* (Cockcroft-Gault formula)
Hemoglobin*
Surgical/Interventional history
Lower extremity bypass
Lower extremity aneurism repair
Peripheral vascular intervention
Major lower extremity amputation
Minor lower extremity amputation
Periprocedural
Indication
Urgency
Arterial access site (femoral or nonfemoral)
Procedural
Access guidance
Anticoagulant
Pharmacologic thrombolysis
Fluoroscopy time
Sheath size
Vascular closure device
Best technical result
*Analyzed as a continuous and categorical variable.
Original Research

Table 3. Patient demographic and clinical characteristics at time of procedure

Mean age ± SD (range)
≤70 years
>70 years
Gender
Male
Female
Race
Hispanic
White
Black
Other
Body mass index
<18.5
18.5–24.9
25–29.9
≥30.0
Smoking status
No smoking
Prior
Current
History of hypertension
Diabetes
None
On oral hypoglycemic
On insulin
Chronic obstructive pulmonary disease
Documented coronary artery disease
Peritoneal dialysis or hemodialysis
Symptomatic congestive heart failure
Preoperative ambulatory status
Ambulatory
Ambulatory with assistance
Wheelchair-bound
Bedridden
Prior subinguinal bypass
Prior peripheral vascular intervention
Prior minor lower extremity amputation
Prior major lower extremity amputation
Prior PCI
Prior coronary artery bypass graft
Preoperative medications
Aspirin
P2Y12 antagonists
Chronic anticoagulation
Procedural indication
Claudication
Rest pain
Tissue loss
Acute ischemia
Procedural urgency
Elective
Urgent
Emergent
Arterial access site
Femoral
Other
Access site complication

Derivation cohort
(n=19,683)

Validation cohort
(n=8,314)

68.13 ± 11.30 (30–89)
57.8%
42.2%

67.99 ± 11.27 (30–89)
57.7%
42.3%

58.4%
41.7%

59.2%
40.8%

5.7%
79.2%
12.8%
2.3%

5.8%
79.2%
12.4%
2.6%

0.58
0.97
0.31
0.21

4.1%
30.2%
33.9%
31.9%

3.6%
29.7%
34.3%
32.4%

0.067
0.45
0.48
0.43

20.8%
40.7%
38.5%
87.1%

20.8%
40.9%
38.4%
87.3%

0.97
0.84
0.86
0.69

51.5%
22.1%
26.4%
23.3%
30.1%
7.0%
6.9%

51.6%
22.1%
26.2%
23.8%
29.9%
6.7%
6.8%

0.874
0.912
0.776
0.34
0.84
0.44
0.79

79.7%
14.4%
5.2%
0.8%
16.1%
29.5%
7.7%
4.3%
22.3%
21.6%

80.1%
13.9%
5.2%
0.8%
15.1%
29.5%
6.9%
4.3%
21.7%
21.2%

0.41
0.31
0.99
0.78
0.052
0.96
0.018
0.96
0.39
0.52

72.7%
32.5%
10.7%

72.3%
32.9%
10.9%

0.40
0.57
0.64

67.0%
8.5%
18.9%
5.60%

66.8%
8.9%
18.7%
5.6%

0.81
0.32
0.67
0.99

84.4%
13.7%
1.9%

84.9%
13.2%
1.8%

97.8%
2.2%
3.3%

97.8%
2.2%
3.48%

0.24
0.26
0.74
0.79

P
0.36
0.90
0.18

0.46

PCI, percutaneous coronary intervention; SD, standard deviation.
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the risk score to all patients in the VQI dataset and
comparing ASC rates in patients receiving bivalirudin
or a vascular closure device (VCD) or both bivalirudin
and a VCD to those receiving manual pressure alone.
Multiple procedures on unique patients were included,
but procedures with data missing across any of the
eight score covariates were excluded. Alpha level
≤ 0.05 was considered significant for all analyses. All
statistical analysis was done using SAS Version 9.2
(SAS Institute Inc., Cary, NC).

RESULTS

A total of 27,977 patients with unique PVI met the
inclusion criteria. Patients in the derivation cohort
had similar clinical and demographic characteristics
compared with those in the validation cohort
(Table 3). ASC occurred in 3.3% (n=650) of patients
in the derivation cohort and in 3.48% (n=289) in the
validation cohort (P=0.46 for cross-cohort comparisons).
Predictors of ASC and Model Derivation
Univariate relationships between demographic/
preprocedural characteristics and ASC were age
> 70 years, female gender, white race, body mass index
< 18.5, nonsmoking history, diabetes treated with insulin,
peritoneal or hemodialysis, bedridden preoperative
ambulatory status, prior minor lower extremity
amputation, prior aneurysm repair, procedural indication
of claudication and nonfemoral arterial access site (Table
4). Multivariable predictors of ASC in the derivation
cohort (Table 5) included age > 70, female gender, white
race, diabetes treated with insulin, bedridden ambulatory
status, prior minor amputation, procedural indication of
claudication and nonfemoral arterial access site (model

c-statistic = 0.637). Based on the β coefficient, a weighted
integer value was given to each of the predictors (Figure
2) and eight points were added to each individual score
to maintain totals greater than or equal to zero. Two
predictors, insulin-treated diabetes and prior minor
amputation, were assigned negative values as they were
found to be protective of ASC.
The novel finding of insulin-managed diabetes being
protective for ASC compared to nondiabetics and
diabetics managed on oral hypoglycemic medications
was further evaluated by propensity matching. A cohort
of 4,091 patients in each treatment group, balanced for
clinical, demographic and procedural characteristics,
revealed a lower rate of ASC among insulin-treated
diabetic patients (2.71% vs. 3.72%; OR: 0.723, 95%
CI: 0.564–0.927, P=0.011). A separate propensity
analysis comparing complication rates among diabetics
and nondiabetics in a balanced cohort of 5,521 patients
showed similar ASC rates (3.37% vs. 3.52%; OR:
0.955, 95% CI: 0.774–1.179, P=0.67).
Scores were subsequently grouped into three risk
groups: Low risk (score of 0 to 15; 5,845 [29.7%]
patients with ASC rate of 2.0%), moderate risk (score
of 16 to 27; 12,510 [63.6%] patients with ASC rate
of 3.49%), and high risk (score of 28 to 42; 1,328
[6.75%] patients with ASC rate of 7.23%) (Figure 3A,
3B). ASC requiring intervention (blood transfusion,
thrombin injection or surgical repair) occurred in
0.85% (n=167) of patients in the derivation cohort,
specifically 0.56% (n=33) of low-risk patients, 0.82%
(n=102) of moderate-risk patients and 2.41% (n=32) of
high-risk patients (Figure 3C).

Figure 2. Integer-based risk score to predict access site hematoma

after peripheral vascular intervention (PVI). The sum of points for the
risk factors present in an individual corresponds to the risk for in-hospital
access site complications. Eight points are added to every patient’s
score in order to maintain total equal to or greater than zero.
24

JPCRR • Volume 3, Issue 1 • Winter 2016

Original Research

Table 4. Univariate relationship between baseline characteristics and access site complications in derivation cohort
No ASC
(n=19,033)

ASC
(n=650)

58.17%
41.83%
41.19%

46.15%
53.85%
55.08%

78.96%
21.04%

86.62%
13.38%

4%
96%

6.31%
93.69%

20.67%
79.33%
87.04%

24.31%
75.69%
88%

73.32%
26.68%
30.1%
7.02%
6.96%

81.54%
18.46%
28.35%
4.77%
5.69%

99.26%
0.74%
16.05%
29.57%
7.84%
4.36%

98.46%
1.54%
16.31%
27.23%
3.69%
3.54%

35.29%
64.71%
1.88%
2.12%

39.08%
60.92%
2.46%
3.69%

0.29
0.007

Odds ratio

95% CI

β coefficient

P

1.516
1.656
1.962
2.222
0.754
0.612
1.711
1.657

1.290–1.783
1.428–1.389
1.217–3.163
1.147–4.303
0.611–0.931
0.400–0.937
1.010–2.899
1.085–2.530

0.416
0.503
0.674
0.799
-0.282
-0.491
0.537
0.505

<0.0001
<0.0001
0.0057
0.0179
0.0087
0.0237
0.0457
0.0194

Age
≤70 years
>70 years
Female
Race
White
Other
Body mass index
<18.5 years
≥18.5 years
Smoking status
No smoking
Prior/current
History of hypertension
Diabetes
None/on oral hypoglycemic
On insulin
Documented coronary artery disease
Peritoneal dialysis or hemodialysis
Symptomatic congestive heart failure
Preoperative ambulatory status
Ambulatory
Bedridden
Prior subinguinal bypass
Prior peripheral vascular intervention
Prior minor lower extremity amputation
Prior major lower extremity amputation
Procedural indication
Claudication
Other
Procedural urgency: emergent
Nonfemoral arterial access site

P
<0.001

<0.001
<0.001

0.003

0.025

0.47
<0.001

0.34
0.026
0.21
0.021

0.86
0.20
<0.001
0.31
0.047

ASC, access site complication.

Table 5. Multivariate model generated in the derivation cohort
Age >70 years
Female gender
White race, non-Hispanic
Preoperatively bedridden
Diabetic on insulin
Prior minor amputation
Procedural indication of claudication
Nonfemoral arterial access
CI, confidence interval.

Original Research
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Figure 3. Access site

complication (ASC) rate and
frequency in derivation and
validation cohorts by calculated
risk score group. A: Observed
ASC rate by calculated risk
score and study cohort. B:
Overall ASC frequency by
calculated risk score and study
cohort. C: Frequency of ASC
requiring intervention (blood
transfusion, thrombin injection
or surgical repair) by risk score
and study cohort. D: Access site
complication rate and frequency
by risk score in combined
training and validation cohort.

Model Validation
ASC occurred in 1.5% of the low-risk group, 3.0%
of the moderate-risk group and 4.3% of the highrisk group; risk group frequency was 9.7%, 42.4%
and 48.0%, respectively. The discriminatory power
of the risk model was confirmed by the validation
dataset (Brier score = 0.033), for which the rate of
ASC requiring intervention was 0.83% (69 patients),
specifically 0.50% (n=4), 0.60% (n=21), and 1.10%
(n=44) of patients in the low-, medium- and high-risk
groups, respectively. Figure 3D shows the mean ASC
rates and clinical risk scores for the cohorts combined:
1.9% for low risk (23.8% score frequency), 3.4% for
moderate risk (57.3% score frequency) and 5.1% for
high risk (19.0% score frequency).
Risk Score and Bleeding Avoidance Strategies
Manual compression, bivalirudin, VCD and dual
bleeding avoidance strategy (BAS) with bivalirudin
plus VCD were used in 48.2%, 4.8%, 43.7% and
3.3% of patients, respectively. Overall, ASC was
less frequent in patients who received VCD (2.51%;
P<0.001) and dual BAS (1.32%; P<0.001) compared
with patients who had manual compression alone
(3.98%), but of similar frequency in patients receiving
bivalirudin alone (3.46%; P=0.295) (Figure 4). In a
subpopulation analysis of patients at low predicted
preprocedural risk, those who received bivalirudin
26
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alone had significantly higher ASC frequency than all
other bleeding avoidance strategies, including manual
compression alone (4.60% vs. 1.85%; P=0.013).
However, ASC was less frequent when bivalirudin was
used together with a VCD compared with VCD use
alone in moderate-risk (1.33% vs. 2.50%; P<0.001)
and high-risk (1.56% vs. 3.64%; P<0.001) groups.
Compared with other risk groups, patients at high
predicted preprocedural risk had the lowest odds ratio
from use of a VCD (OR: 0.620, 95% CI: 0.546–0.705,
P<0.001) or dual BAS (OR: 0.322, 95% CI: 0.193–
0.541, P<0.001) versus patients who had manual
compression alone. A VCD alone was least used in
high-risk patients (39% vs. 45% in low-risk and 44%
in moderate-risk; P<0.001); use of dual BAS was not
significantly different among risk groups.

DISCUSSION

The current study developed and validated a risk tool in
27,977 patients undergoing PVI procedures to identify
patients at low, medium and high risk of developing
in-hospital ASC. The variables in the risk tool are
female gender, age > 70, white race, bedridden
ambulatory status, insulin-treated diabetes mellitus,
prior minor amputation, procedural indication of
claudication and nonfemoral arterial access site.
Although many studies have examined predictors
of post-PCI bleeding complications and developed
Original Research

Figure 4. Subpopulation

differential treatment effect
compared to group receiving
manual compression alone. Highand moderate-risk patients had
less access site complications
with the use of closure devices
and closure devices plus
bivalirudin compared to patients
receiving heparin and manual
pressure alone. Patients at low
preprocedural risk did not have
less access site complications with
any bleeding avoidance strategy
compared to those who received
heparin and manual pressure
alone; in fact those who received
bivalirudin and manual pressure
had higher complication rates.
CD, closure device; CI, confidence
interval; OR, odds ratio.

algorithms to stratify patient risk, this study is the first
to do so in the post-PVI population.6-11 Preprocedural
estimation of a patient’s risk may allow clinicians to
modify their practice to improve patient outcomes, as
has been demonstrated in PCI studies.14,15
Predictors of Access Site Complication
Despite different patient population and outcome
measures, the current risk tool shares age, female
gender and procedural indication with nearly all
PCI bleeding models.6-11 Prior minor amputation and
preoperative bedridden status, which likely reflect
disease severity and patient frailty, respectively, are
predictors of ASC post-PCI. White race was predictive
of bleeding, and disparity in bleeding rates among
races has been previously identified in PVI, PCI and
vascular interventions.5,16,17 Nonfemoral arterial access
in PVI also has been associated with ASC and may
be related to transbrachial access, which is associated
with puncture site complications in PCI.5,18-20 Two
factors –– diabetes treated with insulin and prior
minor amputation –– proved protective against ASC
when compared to all other patients in multivariate
analysis, and this relationship also was observed in
insulin-treated diabetics after propensity matching
of preprocedural and procedural variables. This is a
novel finding that differs from predictors in patients
following PCI. The authors hypothesize that this may
be explained by the biochemical and biomechanical
changes studied in vitro that increase in the stability
Original Research

of aortic collagen, resulting in increased tensile
strength of vessels.8,9,21 Further studies are warranted
to elucidate if this relationship holds in peripheral
arteries. Insulin therapy in diabetics may serve as a
measure of increased disease duration and severity
(as compared to diabetics treated with oral agents);
similarly, a history of minor amputation may be more
likely in advanced vasculopaths. Again, these are
hypotheses; the mechanism of protection is beyond the
scope of this investigation.
Although there was a relationship between dialysis
and ASC on univariate analysis, multivariate analysis
revealed no relationship between dialysis, glomerular
function or creatinine and ASC. This differs from
previously cited PCI risk scores and may be explained
by the fact that renal dysfunction, as a bleeding
diathesis, may increase non-access site bleeding, which
was not included in our study. Similarly, most PCI
bleeding scores include anemia as a bleeding predictor,
a relationship not held in the VQI population. This,
again, may be due to non-access site bleeding, including
gastrointestinal bleeding in patients with prior bleeding
disorders, which has been shown to increase post-PCI
bleeding.7 Heart failure is the most important predictor
of bleeding, presumably including ASC, in most PCI
risk tools due to associated comorbidities. These
include postprocedural intra-aortic balloon pump
placement, which has been associated with a greater
than eight times higher risk of post-PCI bleeding.7
www.aurora.org/jpcrr
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Predicting the use of intra-aortic balloon pumps in
patients with preprocedural signs of cardiogenic shock
and non-access site bleeding complication in those
with prior hemorrhagic diathesis also may explain the
slightly higher c-statistics obtained in PCI bleeding
risk tools.
Bivalirudin/VCD
The purpose of this tool was to estimate preprocedural
risk for post-PVI ASC in order to guide clinicians’ use
of adjunct bleeding avoidance strategies to improve
patient safety. We realize that procedural characteristics
can change intraprocedural characteristics, including
the use of VCDs and anticoagulants, however these
were not included in the modeling process due to the
potential for selection bias and the potential for incorrect
dosing resulting in increased bleeding rates.11 The
unadjusted subpopulation analysis comparing efficacy
of bleeding avoidance strategies in PVI mirrored many
findings in the National Cardiovascular Data Registry
population studied for PCI.22,23 Overall, patients who
received bivalirudin alone tended to have fewer ASC,
despite this effect not being significant in the low
preprocedural risk group. Patients who received a VCD
with or without bivalirudin were less likely to develop
ASC, especially among those at higher calculated
risk. We also found a treatment paradox in that highrisk patients were less likely to receive a VCD. In
this unmatched analysis, bivalirudin when used alone
was not associated with lower ASC rates compared
with patients receiving manual compression alone.
The ENDOvascular Interventions With AngioMAX
(ENDOMAX) trial may elucidate differences in the
intrinsic risk of hemorrhagic complication between
heparin and bivalirudin.24
Study Limitations
Among this study’s strengths are the large, unselected,
multicenter, real-world population analyzed and
the quality of the registry-based data. Certain study
limitations do warrant discussion, including the lack
of accounting for within-hospital clustering and
bleeding complications beyond the arterial access
site or after discharge. Institutional variability may
result in underreporting of post-PVI ASC, and other
procedure-related bleeding complications are not
adjudicated independently by the VQI. Furthermore,
the retrospective nature of the study conveys
inherent limitations, and the multivariable analysis
28
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performed may not have accounted for all relevant
variables resulting in unmeasured confounding.
Lastly, it was not possible to explore the relationship
between bleeding and dosage, timing and duration of
antithrombotic agents. This may be an important factor,
as a recent analysis of post-PCI bleeding determined
that maximum in-laboratory activated clotting time
was the second most important predictor of bleeding
in that population.25 Future studies are necessary to
elucidate these questions.

CONCLUSIONS

Individual risk level for access site complications in
patients undergoing peripheral vascular intervention
may be predicted prior to the procedure. We developed
and validated a simple tool that combines eight
factors to stratify this hazard. Preprocedural ASC risk
assessment could facilitate the individualized selection
of antithrombotic therapy and use of closure devices to
decrease post-PVI complications.

Patient-Friendly Recap
• Complications related to skin punctures for
arterial access are common following vascular
procedures and can result in hospitalization and
death.
• The authors hypothesized a clinically applicable
risk score could be developed by retrospectively
analyzing data from thousands of peripheral
vascular interventions (PVI).
• Six patient factors that significantly increased
risk of site complications and two others that
decreased risk were identified.
• The authors weighed these factors to create a risk
score that helps physicians determine how best
to avoid subsequent internal bleeding and other
complications in patients receiving PVI.

Acknowledgments
The authors express their gratitude to the health
care professionals involved in the Vascular Quality
Initiative, Jennifer Pfaff and Susan Nord of Aurora
Cardiovascular Services for editorial assistance,
and Brian Miller and Brian Schurrer of Aurora Sinai
Medical Center for assistance with the figures.
Original Research

Funding Sources
Dr. Jahangir’s work is partly supported by the
National Heart, Lung, and Blood Institute (R01 grants
HL089542 and HL101240). This study was funded by
the Sullivan Cardiac Research Award provided by the
Aurora Health Care Foundation.
Conflicts of Interest
None.
References

1. Shammas NW, Shammas GA, Jerin M, Dippel EJ, Shammas
AN. In-hospital safety and effectiveness of bivalirudin in
percutaneous peripheral interventions: data from a real-world
registry. J Endovasc Ther. 2010;17:31-6. CrossRef
2. Sheikh IR, Ahmed SH, Mori N, et al. Comparison of safety
and efficacy of bivalirudin versus unfractionated heparin
in percutaneous peripheral intervention: a single-center
experience. JACC Cardiovasc Interv. 2009;2:871-6. CrossRef
3. Walker S, Beasley C, Reeves M. A retrospective study on the
use of heparin for peripheral vascular intervention. Perspect
Vasc Surg Endovasc Ther. 2012;24:63-9. CrossRef
4. Kasapis C, Gurm HS, Chetcuti SJ, et al. Defining the optimal
degree of heparin anticoagulation for peripheral vascular
interventions: insight from a large, regional, multicenter
registry. Circ Cardiovasc Interv. 2010;3:593-601. CrossRef
5. Ortiz D, Jahangir A, Singh M, Allaqaband S, Bajwa TK,
Mewissen MW. Access site complications after peripheral
vascular interventions: incidence, predictors, and outcomes.
Circ Cardiovasc Interv. 2014;7:821-8. CrossRef
6. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict
bleeding in patients with acute coronary syndromes. J Am Coll
Cardiol. 2010;55:2556-66. CrossRef
7. Nikolsky E, Mehran R, Dangas G, et al. Development and
validation of a prognostic risk score for major bleeding in
patients undergoing percutaneous coronary intervention via the
femoral approach. Eur Heart J. 2007;28:1936-45. CrossRef
8. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of
major bleeding in non-ST-segment-elevation myocardial
infarction: the CRUSADE (Can Rapid risk stratification of
Unstable angina patients Suppress Adverse outcomes with
Early implementation of the ACC/AHA Guidelines) Bleeding
Score. Circulation. 2009;119:1873-82. CrossRef
9. Mathews R, Peterson ED, Chen AY, et al. In-hospital major
bleeding during ST-elevation and non-ST-elevation myocardial
infarction care: derivation and validation of a model from the
ACTION Registry®-GWTG™. Am J Cardiol. 2011;107:1136-43.
CrossRef
10. Rao SV, McCoy LA, Spertus JA, et al. An updated bleeding
model to predict the risk of post-procedure bleeding among
patients undergoing percutaneous coronary intervention:
a report using an expanded bleeding definition from the
National Cardiovascular Data Registry CathPCI Registry.
JACC Cardiovasc Interv. 2013;6:897-904. CrossRef
11. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in
patients undergoing percutaneous coronary intervention: the
development of a clinical risk algorithm from the National
Cardiovascular Data Registry. Circ Cardiovasc Interv.
2009;2:222-9. CrossRef

Original Research

12. Shammas NW, Allie D, Hall P, et al. Predictors of in-hospital
and 30-day complications of peripheral vascular interventions
using bivalirudin as the primary anticoagulant: results from
the APPROVE Registry. J Invasive Cardiol. 2005;17:356-9.
13. Cronenwett JL, Kraiss LW, Cambria RP. The Society for
Vascular Surgery Vascular Quality Initiative. J Vasc Surg.
2012;55:1529-37. CrossRef
14. Rao SC, Chhatriwalla AK, Kennedy KF, et al. Pre-procedural
estimate of individualized bleeding risk impacts physicians’
utilization of bivalirudin during percutaneous coronary
intervention. J Am Coll Cardiol. 2013;61:1847-52. CrossRef
15. Strauss C, Porten B, Chavez I, et al. Real time decision
support to guide percutaneous coronary intervention
bleeding avoidance strategies reduces peri-procedural
complications and improves costs. (abstr.) J Am Coll Cardiol.
2013;61(10_S):E1525. CrossRef
16. Mehta RH, Parsons L, Rao SV, Peterson ED; National Registry
of Myocardial Infarction (NRMI) Investigators. Association of
bleeding and in-hospital mortality in black and white patients
with ST-segment-elevation myocardial infarction receiving
reperfusion. Circulation. 2012;125:1727-34. CrossRef
17. Brown HA, Sullivan MC, Gusberg RG, Dardik A, Sosa JA,
Indes JE. Race as a predictor of morbidity, mortality, and
neurologic events after carotid endarterectomy. J Vasc Surg.
2013;57:1325-30. CrossRef
18. Lorenzoni R, Roffi M. Transradial access for peripheral and
cerebrovascular interventions. J Invasive Cardiol. 2013;25:529-36.
19. Baklanov DV, Kim S, Marso SP, Subherwal S, Rao SV.
Comparison of bivalirudin and radial access across a spectrum
of preprocedural risk of bleeding in percutaneous coronary
intervention: analysis from the national cardiovascular data
registry. Circ Cardiovasc Interv. 2013;6:347-53. CrossRef
20. Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, van
der Wieken R. A randomized comparison of percutaneous
transluminal coronary angioplasty by the radial, brachial and
femoral approaches: the access study. J Am Coll Cardiol.
1997;29:1269-75. CrossRef
21. Andreassen TT, Oxlund H. Changes in collagen and elastin of the
rat aorta induced by experimental diabetes and food restriction.
Acta Endocrinol (Copenh). 1987;115:338-44. CrossRef
22. Daugherty SL, Thompson LE, Kim S, et al. Patterns of
use and comparative effectiveness of bleeding avoidance
strategies in men and women following percutaneous
coronary interventions: an observational study from the
National Cardiovascular Data Registry. J Am Coll Cardiol.
2013;61:2070-8. CrossRef
23. Marso SP, Amin AP, House JA, et al. Association between use
of bleeding avoidance strategies and risk of periprocedural
bleeding among patients undergoing percutaneous coronary
intervention. JAMA. 2010;303:2156-64. CrossRef
24. Wayangankar SA, Abu-Fadel MS, Aronow HD, et al.
Hemorrhagic and ischemic outcomes after bivalirudin versus
unfractionated heparin during carotid artery stenting: a
propensity score analysis from the NCDR. Circ Cardiovasc
Interv. 2013;6:131-8. CrossRef
25. Hillegass WB, Brott BC, Chapman GD, et al. Relationship
between activated clotting time during percutaneous
intervention and subsequent bleeding complications. Am
Heart J. 2002;144:501-7. CrossRef
© 2016 Aurora Health Care, Inc.

www.aurora.org/jpcrr

29

